Cigna Earnings Call: Growth Holds Amid PBM Overhaul
Cigna ((CI)) has held its Q4 earnings call. Read on for the main highlights of the call.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Cigna’s Earnings Call Balances Growth Momentum With PBM Overhaul Risks
Cigna’s latest earnings call struck a cautiously optimistic tone, with management leaning into strong revenue and EPS growth, momentum in its EverNorth and specialty businesses, and robust capital returns, while openly acknowledging the costs and execution risks of its shift to a rebate‑free pharmacy benefit model. Executives framed the FTC settlement and broader PBM reform as strategic clarity rather than a constraint, arguing that regulatory alignment and a more transparent, customer‑friendly model will support long-term value creation despite near-term charges, elevated medical costs, and temporary pressure on cash flows.
Double-Digit Revenue Growth and Solid EPS Expansion
Cigna delivered another year of sizable top-line gains, reporting consolidated full-year adjusted revenues of $275 billion, up 11% from the prior year. Adjusted earnings per share reached $29.84, a 9% increase year-over-year, underscoring resilient profitability even as the company absorbed higher medical costs and invested in strategic initiatives. The performance underscores the breadth of Cigna’s diversified portfolio, with contributions from health insurance, specialty services, and its fast-growing EverNorth platform helping to smooth volatility in individual segments.
EverNorth and Specialty Units Drive Earnings Power
EverNorth remained the pivotal earnings engine, posting Q4 revenues of $63.1 billion and pretax adjusted earnings of $2.2 billion. Within EverNorth, specialty and care services stood out, generating $26.7 billion in revenue, up 14% year-over-year, and $1.0 billion in adjusted earnings. Pharmacy benefit services added $36.3 billion in revenue and $1.2 billion in adjusted earnings. Management highlighted the strength of these platforms as key to Cigna’s long-term growth, particularly as specialty drugs and integrated care solutions become a larger share of healthcare spending.
Specialty Scripts Surge and Platform Mix Shifts Upmarket
Specialty pharmacy continues to gain weight in Cigna’s earnings mix. Specialty scripts rose roughly 13% year-over-year in 2025, and specialty and care platforms now account for about 35% of company income, up from roughly 25% just three years ago. Management reiterated a long-term adjusted operating income growth target of 8%–12% for these businesses, indicating confidence that specialty, clinical programs, and care management can outgrow the broader market and offset headwinds in more traditional benefit lines.
PBM Transformation Aligns With Reform and FTC Settlement
A central theme of the call was Cigna’s move to a rebate-free, fee-based PBM model, which management cast as both a regulatory response and a competitive opportunity. The new structure is designed to align with PBM reform efforts and the terms of the recent FTC settlement, shifting economic value toward transparent administration fees and compensation for clinical programs rather than traditional drug rebates. Cigna expects its fully insured Cigna Healthcare book to be on the new model as of January 1, 2027, and is targeting at least 50% of EverNorth’s book to adopt by year-end 2028, setting the stage for a multi-year transition in revenue mix and client contracting.
FTC Settlement Positions Cigna as Customer-Centric
Management framed the global FTC settlement as a strategic clearing event that removes a major regulatory overhang and provides tangible benefits to customers. Cigna expects the settlement’s terms to translate into about $7 billion of out-of-pocket cost relief over the next decade for roughly 100 million customers and patients. By positioning its PBM as more transparent and aligned with end-user savings, the company is betting that the settlement and rebate-free design will strengthen its competitive standing with employers, health plans, and government clients seeking cost certainty and regulatory compliance.
Improved Customer Experience Supports High Retention
The company emphasized a steady focus on service quality and customer loyalty. Net promoter scores improved year-over-year across Cigna’s largest businesses, and prior authorization volumes were cut by 15%, which should ease friction for clinicians and patients. Pharmacy benefit services retention exceeded 97% for 2026 renewals, signaling strong client stickiness despite industry scrutiny. In commercial lines, Cigna’s select segment customers increased about 7%, supporting the narrative that better experience and integrated offerings translate into both retention and selective growth.
Capital Returns and Deleveraging Showcase Financial Discipline
Cigna continued to deploy capital aggressively while improving its balance sheet. In 2025, the company returned more than $5 billion to shareholders, including approximately $3.6 billion of share repurchases (11.9 million shares) and $1.6 billion in dividends. Operating cash flow reached $9.6 billion, underpinning these returns and ongoing investment. Cigna also trimmed leverage, improving its debt-to-capitalization ratio to 43%, a 190 basis point improvement in the fourth quarter alone, and reaffirmed its objective of moving toward roughly 40% debt-to-capital over time.
One-Time Charges Temper Reported Results
Despite healthy underlying trends, Cigna’s reported fourth-quarter results were impacted by special items. The company took after-tax special item charges of $483 million, or $1.82 per share, in Q4, which weighed on GAAP earnings. Management framed these items as largely transitional, associated with restructuring and the strategic shift in the PBM model, and urged investors to focus on adjusted metrics and the underlying earnings trajectory as a better indicator of recurring performance.
Elevated Medical Costs Push MCR Higher
On the insurance side, Cigna Healthcare saw modestly higher medical costs in the fourth quarter, adding roughly 60 basis points to the medical care ratio (around $50 million in additional expense). Looking ahead to 2026, the company guided to an elevated MCR range of 83.7%–84.7%, with the first quarter expected below 81%. Management attributed the higher full-year range to a more inflationary medical cost environment and conservative pricing assumptions, signaling to investors that the company is prioritizing sustainable underwriting margins over aggressive membership growth.
PBM Transition to Pressure Near-Term Cash Flows
The shift to a rebate-free PBM model will require meaningful investment and will temporarily weigh on cash generation. Cigna expects back-half-weighted spending in 2026 to build the infrastructure needed for the new platform. As a result, 2026 operating cash flow is projected at about $9.0 billion, roughly $600 million below 2025 levels, reflecting not only investments but also lower contribution from pharmacy benefit services and the timing of large client renewals. Management argued that, over the long term, margins should be comparable, even as revenue and earnings mix tilts toward admin fees and clinical programs.
Tax Rate Risk From GPO Relocation
An additional complexity from the FTC settlement is the requirement to relocate certain group purchasing organization capabilities from Switzerland to the United States. Management noted that this move could lift Cigna’s effective tax rate by up to about 1% over time if no offsetting actions are taken. While not a near-term shock, investors will be watching how the company manages its tax planning and capital structure to mitigate this potential drag on after-tax earnings.
Membership Mix Reflects Margin-First Strategy
Cigna’s membership outlook underscores a deliberate tilt toward more profitable segments. The company expects about 18.1 million total medical cost customers at the end of 2026, with growth in middle-market, select, and international businesses offset by declines in national accounts and individual exchange membership. Exchange enrollment is projected to fall to fewer than 300,000 as Cigna explicitly prioritizes margin over volume in that line. This mix shift, combined with cautious pricing in a higher-cost environment, is intended to support earnings stability even if headline membership growth is modest.
Transitional Uncertainty and PBM Adoption Risk
While management is confident that the new PBM model will ultimately deliver comparable margins, they acknowledged that the transition introduces uncertainty. The plan calls for broad adoption by 2028, but the pace of client migration will depend on execution and customer choice, leaving room for variation in the revenue and earnings trajectory. The shift from rebate economics to fee-based and clinical program compensation will also change how investors evaluate EverNorth’s performance, potentially complicating comparisons to historical results during the transition phase.
Stop-Loss and Exchange Distort Year-Over-Year Comparisons
Cigna cautioned that certain one-time effects in the individual exchange business bolstered the 2025 medical care ratio, making year-over-year comparisons less straightforward. Additionally, stop-loss products experienced a slightly higher MCR in 2025 versus 2024, consistent with prior commentary. These factors, combined with the broader cost environment and PBM transition, mean investors will need to look through short-term noise in MCR trends to assess the underlying earnings power of the healthcare segment.
Guidance Signals Steady Growth Amid Transformation
For 2026, Cigna guided to consolidated adjusted revenues of approximately $280 billion and adjusted EPS of at least $30.25, implying modest EPS growth on top of an already elevated earnings base. EverNorth is expected to deliver at least $6.9 billion in adjusted earnings, with over 20% of that coming in the first quarter, while Cigna Healthcare is projected to generate at least $4.5 billion, with more than 30% of its annual earnings in Q1. The company anticipates an 83.7%–84.7% medical care ratio for Cigna Healthcare, an enterprise adjusted SG&A ratio near 5%, a consolidated adjusted tax rate around 19%, and operating cash flow of about $9 billion. Capital expenditures are pegged at roughly $1.3 billion, shareholder dividends at about $1.6 billion (with a quarterly dividend of $1.56 per share), and weighted average shares between 261–265 million, all while continuing to work down leverage toward a 40% debt-to-capital target.
Cigna’s earnings call painted a picture of a company leaning into its strengths—EverNorth, specialty, and disciplined capital returns—while embarking on a complex but potentially value-creating PBM overhaul. Investors will have to navigate a period of higher medical costs, one-time charges, and softer cash flow, but management’s focus on regulatory clarity, customer affordability, and margin-protective membership choices suggests a strategy aimed at sustaining earnings growth rather than chasing volume. If execution on the new PBM model matches the confidence expressed on the call, Cigna could emerge with a more transparent, durable earnings profile that appeals to both customers and long-term shareholders.
